Loading clinical trials...
Loading clinical trials...
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Conditions
Interventions
Orforglipron
Placebo
Locations
80
United States
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona, United States
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona, United States
Norcal Endocrinology & Internal Medicine
San Ramon, California, United States
Southern California Clinical Research
Santa Ana, California, United States
Care Access - Thousand Oaks
Thousand Oaks, California, United States
Accel Research Sites - DeLand Clinical Research Unit
DeLand, Florida, United States
Start Date
May 15, 2025
Primary Completion Date
August 1, 2027
Completion Date
August 1, 2027
Last Updated
April 24, 2026
NCT07037459
NCT07351045
NCT07508241
NCT07244458
NCT05746039
NCT07311850
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions